Nemolizumab for treating prurigo nodularis [ID6451]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ruxolitinib for Prurigo Nodularis [ID6571]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC